Jeff Albers

CEO, President and Member of the Board of Directors

Jeff has more than 15 years of experience in leadership roles in the biopharmaceutical industry. He joined Blueprint Medicines after a successful tenure as president of Algeta, where he oversaw the commercial and business functions during a period of exponential growth in staff and revenue. Under his leadership, Algeta gained FDA approval and launched prostate cancer drug XOFIGO® (radium Ra 223 dichloride) on an expedited timeline, exceeding revenue forecasts and ultimately supporting a successful acquisition by Bayer. Prior to Algeta, Jeff held senior commercial and corporate development positions at Genzyme (now a division of Sanofi), most recently as vice president of the US hematology and oncology business unit. Earlier in his career, Jeff was a life sciences corporate attorney at Mintz Levin Cohn Ferris Glovsky & Popeo. He holds a B.S. from Indiana University and an MBA and J.D. from Georgetown University.

Anthony L. Boral, M.D., Ph.D.

Chief Medical Officer

Andy brings extensive experience in oncology clinical development. Prior to joining Blueprint Medicines, he was executive director of oncology clinical research and deputy site head at Novartis Institutes for Biomedical Research (NIBR), where he was responsible for the clinical aspects of various first-in-human compounds, including ceritinib (an ALK inhibitor) and immune checkpoint inhibitor programs. Prior to Novartis, he spent eight years at Millennium Pharmaceuticals, including four years as vice president of oncology clinical research. In that role, Andy was responsible for various aspects of the clinical development of Velcade® (bortezomib), as well as the company’s growing early-stage pipeline. Before moving to industry, Andy was a thoracic oncologist at Massachusetts General Hospital (MGH), where his research focused on clinical studies of novel agents. Andy received his M.D. and a Ph.D. in molecular genetics from the Albert Einstein College of Medicine and trained in internal medicine at MGH. He completed his fellowship in medical oncology at the Dana-Farber Cancer Institute/Partners program.

Marion Dorsch, Ph.D.

Chief Scientific Officer

Marion joins Blueprint Medicines from Agios Pharmaceuticals, Inc. where she served as Vice President of Biology. In this role, she was responsible for novel target validation, drug discovery, and biomarker strategy across Agios’ cancer, rare genetic diseases and immuno-oncology portfolios. During her tenure at Agios, Marion contributed to the successful advancement of several molecules targeting defined genetic lesions into clinical trials. Prior to joining Agios, Marion was the Director of Cancer Biology at Sanofi Oncology, where she oversaw drug discovery efforts. Earlier in her career, Marion served as research project leader for sonidegib (Odomzo), now approved in the U.S. and EU for the treatment of locally advanced basal cell carcinoma, at the Novartis Institutes for Biomedical Research and also worked in Inflammation Discovery at Millennium Pharmaceuticals. Marion received her Ph.D. in Biology from the Free University of Berlin, Germany and was a postdoctoral fellow at Columbia University in New York.

Debbie Durso-Bumpus

Senior Vice President, Human Resources

Debbie is an accomplished human resources executive with a focus on providing strategic direction to companies on people matters, managing rapid growth and creating and maintaining high performance cultures. Most recently, Debbie served as the interim head of human resources for Cubist Pharmaceuticals, Inc., where she was appointed to lead the post-merger human resource integration following the acquisition of Cubist by Merck.  Prior to this role, she was the global senior director for talent management and organizational development at Cubist, where she was primarily responsible for building talent and leadership strength and depth while managing change on a global scale to create a cohesive and highly differentiated culture. Prior to Cubist, Debbie served as the North American manager of talent acquisition and workforce planning at Holcim, Inc., in Waltham, MA. She serves as a member of the board of directors for the Massachusetts Biotechnology Education Foundation, a nonprofit organization committed to supporting science and biotechnology education in Massachusetts through school programs, workforce training and lifelong learning. Debbie earned a B.S. in business management from Bentley University.

Kate Haviland

Chief Business Officer

Kate brings an impressive breadth of experience and leadership within the biopharmaceutical industry and a substantial background in business development, commercial and strategic planning and program management.  Prior to joining Blueprint Medicines, she served as Vice President, Rare Diseases and Oncology Program Leadership at Idera Pharmaceuticals. In this role, she oversaw all aspects of the product development strategy for Idera Pharmaceuticals’ rare disease and oncology pipeline programs, including preclinical research, manufacturing and drug supply, regulatory affairs, clinical development and execution and commercial planning. Prior to joining Idera Pharmaceuticals, Kate was Head of Commercial Development at Sarepta Therapeutics, where she was responsible for product development and commercial planning and for cultivating relationships with key opinion leaders and patient advocacy groups.  In addition, Kate previously served as Executive Director of Commercial Development at PTC Therapeutics and held corporate development and project management roles at Genzyme. She holds a B.A. from Wesleyan University with a double major in Biochemistry/Molecular Biology and Economics and an M.B.A. from Harvard Business School.

Mike Landsittel

Vice President, Finance

Mike has over 15 years of experience as a senior finance professional with a strategic and operational focus. Prior to joining Blueprint Medicines, Mike served as senior director of finance at Algeta US, where he led the US organization’s finance and operations efforts, which ultimately supported the successful  launch of the prostate cancer drug XOFIGO® (radium Ra 223 dichloride).  Before joining Algeta, Mike was the director of financial planning at Infinity Pharmaceuticals, Inc., where he was responsible for budgeting and forecasting, including support of Infinity’s long range planning and financing activities. Prior to Infinity, Mike held multiple business development and strategic planning roles for nearly 10 years at Genzyme. Mike is a registered CPA in the state of Illinois. He holds a B.B.A from the University of Michigan and an M.B.A. from the Tuck School of Business at Dartmouth College.

Christoph Lengauer, Ph.D.

Executive Vice President

Christoph has a proven record in cancer drug discovery, including contributing to 19 development candidates, 13 drugs or programs that reached first-in-human clinical trials and three approved drugs. He joined Blueprint Medicines from Sanofi, where he was vice president and global head of oncology drug discovery and preclinical development. Before joining Sanofi, Christoph was executive director and senior unit head of oncology discovery at the Novartis Institutes for Biomedical Research (NIBR). Prior to Novartis, Christoph was an associate professor at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine where he worked with Drs. Bert Vogelstein and Ken Kinzler for more than ten years. Christoph discovered that all cancers are genetically unstable and was involved in the identification of several oncogenic driver genes. He has authored more than 100 scientific articles published in top-tier scientific journals, including Cell, Nature and Science. He is a strong and outspoken advocate of patients’ rights and is featured in the New York Times bestseller “The Immortal Life of Henrietta Lacks.” Christoph studied human genetics in Salzburg, Austria, and received his Ph.D. from the University of Heidelberg, Germany and his MBA with a focus on medical services management from the Johns Hopkins Carey Business School. Christoph has received numerous awards, including the Boveri Award in Cancer Genetics, the Benjamin Baker Scholar award, and a V Foundation scholarship.  He was awarded the Novartis Oncology’s President’s Award for top innovator and has been elected to membership in the Johns Hopkins Society of Scholars.

Tracey McCain

Chief Legal Officer

Tracey is an experienced legal professional with over 20 years of legal, management and transactional experience in the biopharmaceutical industry.  Most recently, Tracey served as senior vice president & head of legal for Sanofi Genzyme, a global business unit of Sanofi, as well as a member of Sanofi Genzyme’s executive leadership team and as a member of the leadership team for Sanofi’s global legal department.  After Genzyme Corporation was acquired by Sanofi, Tracey became Genzyme’s general counsel.  In her capacity as Genzyme’s general counsel, Tracey was responsible for all aspects of its legal department in the United States and throughout Europe, including general corporate, commercial and intellectual property legal matters, and support of business development initiatives.  Prior to Genzyme’s acquisition, Tracey was also responsible for managing the securities and employment law teams and support of non-patent litigation.  Before Genzyme, Tracey was an associate at the law firm Palmer & Dodge LLP. Tracey received her B.A. in political science from the University of Pennsylvania and her J.D. from Columbia University School of Law where she was a Harlan Fiske Stone Scholar.

Christopher Murray, Ph.D.

Senior Vice President, Technical Operations

Chris has over 25 years of commercial and clinical manufacturing experience in the biopharmaceutical industry.  Most recently, Chris served as Vice President, Technical Operations at ARIAD Pharmaceuticals, Inc. (ARIAD) from January 2014 to May 2017.  In this role, Chris oversaw all aspects of commercial and clinical manufacturing, supply chain and logistics, process development, quality control and analytical chemistry for ARIAD’s approved products and product candidates, including Iclusig® (ponatinib) and Alunbrig® (brigatinib).  From 2004 to December 2013, Chris held multiple roles of increasing responsibility at ARIAD related to process development, manufacturing and clinical supply.  Prior to joining ARIAD, Chris served in various positions with Allos Therapeutics, Inc. and Hauser Inc. related to clinical and commercial manufacturing and supply of active pharmaceutical ingredient.  Chris holds a B.S. from Hope College with a major in chemistry and a Ph.D. in chemistry from the University of Chicago.

Christina Rossi

Chief Commercial Officer

Christy has close to 20 years of global pharmaceutical and biotechnology experience. Prior to joining Blueprint, she served as the Multiple Sclerosis (MS) Business Unit Head, North America, at Sanofi Genzyme. In this role, she oversaw all aspects of the financial performance of Sanofi Genzyme’s MS franchise and increased market share for existing products, led the launch of new therapies and optimized operations to accelerate patient access. Previously, Christy served as Vice President, MS Sales, and Vice President, MS Patient and Provider Services, at Sanofi Genzyme. Prior to joining Sanofi Genzyme, she held various roles at Biogen, Inc., including Head, Commercial Strategy for Eidetica Biopharma GmbH, Biogen’s biosimilar-focused venture, and U.S. Brand Leader for TYSABRI® (natalizumab). In addition, she consulted in the healthcare practice at the Boston Consulting Group. Christy holds a B.S. in biology, cum laude, from Duke University and an M.B.A. from Harvard Business School.